<?xml version='1.0' encoding='utf-8'?>
<document id="22563046"><sentence text="In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites." /><sentence text="The in vivo drug-drug interaction (DDI) risks associated with cytochrome P450 inhibitors that have circulating inhibitory metabolites cannot be accurately predicted by conventional in vitro-based methods" /><sentence text=" A novel approach, in vivo information-guided prediction (IVIP), was recently introduced for CYP3A- and CYP2D6-mediated DDIs" /><sentence text=" This technique should be applicable to the prediction of DDIs involving other important cytochrome P450 metabolic pathways" /><sentence text=" Therefore, the aims of this study were to extend the IVIP approach to CYP2C9-mediated DDIs and evaluate the IVIP approach for predicting DDIs associated with inhibitory metabolites" /><sentence text=" The analysis was based on data from reported DDIs in the literature" /><sentence text=" The IVIP approach was modified and extended to CYP2C9-mediated DDIs" /><sentence text=" Thereafter, the IVIP approach was evaluated for predicting the DDI risks of various inhibitors with inhibitory metabolites" /><sentence text=" Although the data on CYP2C9-mediated DDIs were limited compared with those for CYP3A- and CYP2D6-mediated DDIs, the modified IVIP approach successfully predicted CYP2C9-mediated DDIs" /><sentence text=" For the external validation set, the prediction accuracy for area under the plasma concentration-time curve (AUC) ratios ranged from 70 to 125%" /><sentence text=" The accuracy (75-128%) of the IVIP approach in predicting DDI risks of inhibitors with circulating inhibitory metabolites was more accurate than in vitro-based methods (28-805%)" /><sentence text=" The IVIP model accommodates important confounding factors in the prediction of DDIs, which are difficult to handle using in vitro-based methods" /><sentence text=" In conclusion, the IVIP approach could be used to predict CYP2C9-mediated DDIs and is easily modified to incorporate the additive effect of circulating inhibitory metabolites" /><sentence text="" /></document>